Cargando…

Validation of the children international IgA nephropathy prediction tool based on data in Southwest China

BACKGROUND: Immunoglobulin A nephropathy (IgAN) is one of the most common kidney diseases leading to renal injury. Of pediatric cases, 25%–30% progress into end-stage kidney disease (ESKD) in 20–25 years. Therefore, predicting and intervening in IgAN at an early stage is crucial. The purpose of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Xixi, Li, Jiacheng, Tao, Chengrong, Jiao, Jia, Wan, Junli, Zhong, Cheng, Yang, Qin, Shi, Yongqi, Zhang, Gaofu, Yang, Haiping, Li, Qiu, Wang, Mo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327563/
https://www.ncbi.nlm.nih.gov/pubmed/37425278
http://dx.doi.org/10.3389/fped.2023.1183562
_version_ 1785069654233841664
author Yu, Xixi
Li, Jiacheng
Tao, Chengrong
Jiao, Jia
Wan, Junli
Zhong, Cheng
Yang, Qin
Shi, Yongqi
Zhang, Gaofu
Yang, Haiping
Li, Qiu
Wang, Mo
author_facet Yu, Xixi
Li, Jiacheng
Tao, Chengrong
Jiao, Jia
Wan, Junli
Zhong, Cheng
Yang, Qin
Shi, Yongqi
Zhang, Gaofu
Yang, Haiping
Li, Qiu
Wang, Mo
author_sort Yu, Xixi
collection PubMed
description BACKGROUND: Immunoglobulin A nephropathy (IgAN) is one of the most common kidney diseases leading to renal injury. Of pediatric cases, 25%–30% progress into end-stage kidney disease (ESKD) in 20–25 years. Therefore, predicting and intervening in IgAN at an early stage is crucial. The purpose of this study was to validate the availability of an international predictive tool for childhood IgAN in a cohort of children with IgAN treated at a regional medical centre. METHODS: An external validation cohort of children with IgAN from medical centers in Southwest China was formed to validate the predictive performance of the two full models with and without race differences by comparing four measures: area under the curve (AUC), the regression coefficient of linear prediction (PI), survival analysis curves for different risk groups, and R(2)D. RESULTS: A total of 210 Chinese children, including 129 males, with an overall mean age of 9.43 ± 2.71 years, were incorporated from this regional medical center. In total, 11.43% (24/210) of patients achieved an outcome with a GFR decrease of more than 30% or reached ESKD. The AUC of the full model with race was 0.685 (95% CI: 0.570–0.800) and the AUC of the full model without race was 0.640 (95% CI: 0.517–0.764). The PI of the full model with race and without race was 0.816 (SE = 0.006, P < 0.001) and 0.751 (SE = 0.005, P < 0.001), respectively. The results of the survival curve analysis suggested the two models could not well distinguish between the low-risk and high-risk groups (P = 0.359 and P = 0.452), respectively, no matter the race difference. The evaluation of model fit for the full model with race was 66.5% and without race was 56.2%. CONCLUSIONS: The international IgAN prediction tool has risk factors chosen based on adult data, and the validation cohort did not fully align with the derivation cohort in terms of demographic characteristics, clinical baseline levels, and pathological presentation, so the tool may not be highly applicable to children. We need to build IgAN prediction models that are more applicable to Chinese children based on their particular data.
format Online
Article
Text
id pubmed-10327563
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-103275632023-07-08 Validation of the children international IgA nephropathy prediction tool based on data in Southwest China Yu, Xixi Li, Jiacheng Tao, Chengrong Jiao, Jia Wan, Junli Zhong, Cheng Yang, Qin Shi, Yongqi Zhang, Gaofu Yang, Haiping Li, Qiu Wang, Mo Front Pediatr Pediatrics BACKGROUND: Immunoglobulin A nephropathy (IgAN) is one of the most common kidney diseases leading to renal injury. Of pediatric cases, 25%–30% progress into end-stage kidney disease (ESKD) in 20–25 years. Therefore, predicting and intervening in IgAN at an early stage is crucial. The purpose of this study was to validate the availability of an international predictive tool for childhood IgAN in a cohort of children with IgAN treated at a regional medical centre. METHODS: An external validation cohort of children with IgAN from medical centers in Southwest China was formed to validate the predictive performance of the two full models with and without race differences by comparing four measures: area under the curve (AUC), the regression coefficient of linear prediction (PI), survival analysis curves for different risk groups, and R(2)D. RESULTS: A total of 210 Chinese children, including 129 males, with an overall mean age of 9.43 ± 2.71 years, were incorporated from this regional medical center. In total, 11.43% (24/210) of patients achieved an outcome with a GFR decrease of more than 30% or reached ESKD. The AUC of the full model with race was 0.685 (95% CI: 0.570–0.800) and the AUC of the full model without race was 0.640 (95% CI: 0.517–0.764). The PI of the full model with race and without race was 0.816 (SE = 0.006, P < 0.001) and 0.751 (SE = 0.005, P < 0.001), respectively. The results of the survival curve analysis suggested the two models could not well distinguish between the low-risk and high-risk groups (P = 0.359 and P = 0.452), respectively, no matter the race difference. The evaluation of model fit for the full model with race was 66.5% and without race was 56.2%. CONCLUSIONS: The international IgAN prediction tool has risk factors chosen based on adult data, and the validation cohort did not fully align with the derivation cohort in terms of demographic characteristics, clinical baseline levels, and pathological presentation, so the tool may not be highly applicable to children. We need to build IgAN prediction models that are more applicable to Chinese children based on their particular data. Frontiers Media S.A. 2023-06-23 /pmc/articles/PMC10327563/ /pubmed/37425278 http://dx.doi.org/10.3389/fped.2023.1183562 Text en © 2023 Yu, Li, Tao, JIao, Wan, Zhong, Yang, Shi, Fu, Yang, Li and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Yu, Xixi
Li, Jiacheng
Tao, Chengrong
Jiao, Jia
Wan, Junli
Zhong, Cheng
Yang, Qin
Shi, Yongqi
Zhang, Gaofu
Yang, Haiping
Li, Qiu
Wang, Mo
Validation of the children international IgA nephropathy prediction tool based on data in Southwest China
title Validation of the children international IgA nephropathy prediction tool based on data in Southwest China
title_full Validation of the children international IgA nephropathy prediction tool based on data in Southwest China
title_fullStr Validation of the children international IgA nephropathy prediction tool based on data in Southwest China
title_full_unstemmed Validation of the children international IgA nephropathy prediction tool based on data in Southwest China
title_short Validation of the children international IgA nephropathy prediction tool based on data in Southwest China
title_sort validation of the children international iga nephropathy prediction tool based on data in southwest china
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10327563/
https://www.ncbi.nlm.nih.gov/pubmed/37425278
http://dx.doi.org/10.3389/fped.2023.1183562
work_keys_str_mv AT yuxixi validationofthechildreninternationaliganephropathypredictiontoolbasedondatainsouthwestchina
AT lijiacheng validationofthechildreninternationaliganephropathypredictiontoolbasedondatainsouthwestchina
AT taochengrong validationofthechildreninternationaliganephropathypredictiontoolbasedondatainsouthwestchina
AT jiaojia validationofthechildreninternationaliganephropathypredictiontoolbasedondatainsouthwestchina
AT wanjunli validationofthechildreninternationaliganephropathypredictiontoolbasedondatainsouthwestchina
AT zhongcheng validationofthechildreninternationaliganephropathypredictiontoolbasedondatainsouthwestchina
AT yangqin validationofthechildreninternationaliganephropathypredictiontoolbasedondatainsouthwestchina
AT shiyongqi validationofthechildreninternationaliganephropathypredictiontoolbasedondatainsouthwestchina
AT zhanggaofu validationofthechildreninternationaliganephropathypredictiontoolbasedondatainsouthwestchina
AT yanghaiping validationofthechildreninternationaliganephropathypredictiontoolbasedondatainsouthwestchina
AT liqiu validationofthechildreninternationaliganephropathypredictiontoolbasedondatainsouthwestchina
AT wangmo validationofthechildreninternationaliganephropathypredictiontoolbasedondatainsouthwestchina